DHL Group is investing €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector. With 40% of the investment allocated to North America, 10% to Latin America, 25% to Asia Pacific, and 25% to the EMEA region, DHL is expanding its global footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.

The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints—from storage, order fulfillment, and distribution to global shipping and last-mile delivery—creating even more resilient, scalable, and responsive supply chains for customers. A significant part of the investment will be allocated to establishing new cross-divisional GPD-certified Pharma Hubs for multi-temperature shipment lanes, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions to ensure sustainable delivery.

DHL is also investing in high-quality, specialized cooling infrastructure to accommodate low and ultra-low temperature ranges. Additionally, the Group will implement IT systems that provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.

With its new sector brand DHL Health Logistics, the Group consolidates its life sciences and healthcare expertise under one unified umbrella. This creates a seamless, end-to-end experience for customers, simplifying the management of complex, cross-border supply chains with confidence, agility and high-quality service. The approach is designed to meet the needs of pharmaceutical, biopharma, and medical customers who require agile, connected logistics solutions that go beyond traditional service lines.

“Our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create—ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”

Through this strategic investment, DHL Group is not only reinforcing its commitment to the life science and healthcare sector but also demonstrating a dedication to patient care by ensuring the efficient and reliable delivery of essential pharmaceutical products, clinical trials and cell & gene therapies.

More DHL Group News

DHL Group recently acquired CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies.